As it has become clear that HIV causes a progressive breakdown in immune competence that can be precisely measured, the introduction of diagnostic tests in placebo-controlled clinical trials has taken on a new importance. The task for clinical immunologists, namely to standardize these techniques through international collaboration using current understanding of pathogenesis, was the subject of a recent workshop*.